Press Releases – Genocea Biosciences

– Presentation of GEN-003 12-Month Data Featured in ASM Press Briefing – – Phase 2 GEN-004 Results Highlight Potential for Future Development of Vaccine for Pneumococcal Disease – CAMBRIDGE, Mass., June 09, 2016 (GLOBE NEWSWIRE) — Genocea Biosciences, Inc. The issuer is solely responsible for the content of this announcement. 2014 Jan 16;370(3):201-10. Genocea’s pipeline includes GEN-003, a novel T cell-enabled immunotherapy for genital herpes in Phase 2 clinical development, and earlier-stage investments in immuno-oncology. Several co-authors are company employees. And if a client needs another promoter or another reporter, GEG Tech will design a customized new lentiviral vector. Dimensional Fund Advisors LP bought a new stake in shares of Genocea Biosciences during the second quarter valued at approximately $143,000.

Two of these clinically backed remedies are Novirin and Gene-Eden-VIR. Neither the placebo nor the monovalent vaccine groups achieved statistical significance on this endpoint at nine months after vaccination. Viral shedding rate reductions were measured to demonstrate the efficacy of the new formulation. In the U.S., an estimated 50-60 million people are affected. The company’s majority investor is SANTO Holding. Clark presented data demonstrating the Company’s belief that GEN-003 could have upwards of $2 billion global revenue potential if successfully developed worldwide. Dr.


Additionally, DNA vaccines have the potential to achieve proof of concept more quickly and cost-effectively than conventional vaccines, and can be manufactured using uniform methods of fermentation and purification, allowing significantly faster development and production. Infections can also be unrecognized, meaning that infected individuals, with or without symptoms, can shed HSV and so can infect sexual partners,” said Dr. STD test results; Using latex condoms the right way every time you have sex. GEN-004 – Vaccine for the prevention of infections by all serotypes of pneumococcus. HSV-2 infection can cause recurring, painful genital sores, and can be stigmatizing and produce considerable psychological distress in patients. ”We are very pleased with these data as HSV therapy has not seen much innovation in more than a decade. Barriers met in dissertation abstract Barriers met in dissertation abstract.

Transplant recipients are particularly at risk because they take medicines that suppress their immune system. EDT. “In spite of available therapeutic options there seems to be a great demand for a new, well tolerated and efficacious drug for people suffering from genital herpes”. The AiCuris portfolio today comprises seven clinical development programs including letermovir, a prophylactic treatment against human cytomegalovirus (HCMV) in bone marrow transplant patients, licensed to Merck & Co. Meanwhile, Vical said that it will follow up on all patients in the study for safety for 12 months and efficacy for 9 months after they receive their final vaccine dose. public pharmaceutical company that discovers, develops and commercializes vaccines based on the discovery of antigens that induce T cell immunity. About herpes Herpes simplex viruses (HSV) are widespread in the human population (seroprevalence up to 100%, depending on geographic area and subpopulation), and are divided into herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2).

7,628,993 covering DNA vaccines for herpes simplex virus type 2 (HSV-2). The analyst notes that GEN-003 has displayed reduced rates of genital lesion and viral shedding compared with baseline rates and its improved dosing frequency makes the drug an attractive alternative to current daily antivirals. The goal of the trial was to compare the efficacy of four different doses of AIC316 (5, 25, and 75 mg once daily, or 400 mg once weekly) and placebo with respect to the suppression of HSV shedding. All participants received the study drug or placebo daily or weekly for 4 weeks. Wuppertal, Germany, October 28, 2016 – AiCuris Anti-infective Cures GmbH, a leading company in the discovery and development of drugs against infectious diseases, today announced, that it will host in cooperation with the BIO Clustermanagement NRW GmbH a press conference and mini-symposium to celebrate its 10th Anniversary at the BIO-Europe(R) 2016 – 22nd Annual International Partnering Conference being held November 7-9, 2016 in Cologne, Germany. These results, along with previously presented results from guinea pig studies, support the company’s decision in early 2012 to advance toward clinical testing, which is expected to begin in 2013. Wuppertal, December 1st, 2016 – AiCuris Anti-infective Cures GmbH, a leading company in the discovery and development of drugs against infectious diseases, today announced that the first subject has been enrolled in a clinical phase 2 efficacy and safety study evaluating topical pritelivir, a small molecule helicase-primase inhibitor, for the treatment of recurrent labial herpes (cold sores), the most evident sign of herpes simplex virus type 1 (HSV-1).

Vical Incorporated VICL presented data from a phase I/II study on its genital herpes vaccine at a meeting of the American Society for Microbiology. 08.11.2016 / 13:00 The issuer is solely responsible for the content of this announcement. In one of two studies presented, Genocea researchers studied the T cell immune responses to each HSV-2 protein among patients with HSV-2 infection or exposure.